Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 26;111(5):837-42.
doi: 10.1038/bjc.2014.339. Epub 2014 Jul 8.

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer

R Exner  1 , Z Bago-Horvath  2 , R Bartsch  3 , M Mittlboeck  4 , V P Retèl  5 , F Fitzal  1 , M Rudas  2 , C Singer  6 , G Pfeiler  6 , M Gnant  1 , R Jakesz  1 , P Dubsky  1
Affiliations

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer

R Exner et al. Br J Cancer. .

Abstract

Background: Validated multigene signatures (MGS) provide additional prognostic information when evaluating clinical features of ER(+), HER2(-) early breast cancer. We have studied the quantitative and qualitative impact of MGS on multidisciplinary team (MDT) recommendations.

Methods: We prospectively recruited 75 ER(+), HER2(-) breast cancer patients. Inclusion was based on biopsy assessment of grade, hormone receptor status, HER2, clinical tumour and nodal status. A fresh tissue sample was sent for MammaPrint (MP), TargetPrint analysis at surgery. Clinical risk was decided by the MDT in the absence of MP results and repeated following the collection of MP results. Decision changes were recorded and a health technology assessment was undertaken to compare cost effectiveness.

Results: The majority of patients were assigned low to intermediate clinical risk by the MDT. According to MP, 76% were low risk. A very high correlation between local IHC and the TargetPrint assessment was shown. In over a third of patients, discordance between clinical and molecular risk was observed. Decision changes were recorded in half of these cases (18.6%) and resulted in two out of three patients not requiring chemotherapy. The use of MP was also found to be more cost effective.

Conclusions: The multigene signature MP revealed clinical and molecular risk discordance in a third of patients. The impact of this on MDT recommendations was most profound in cases where few clinical risk factors were observed and enabled some women to forgo chemotherapy. The use of MGS is unlikely to have an impact in either clinically low-risk women or in patients with more than one relative indication for chemotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation of proliferation (MIB-1) and gene expression analysis MammaPrint (MP).
See this image and copyright information in PMC

References

    1. Albain KS, Paik S, Van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009;18 (Suppl 3:S141–S145. - PubMed
    1. Azim HAJr, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, Andre F, Loi S, Swanton C. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol. 2013;24:647–654. - PMC - PubMed
    1. Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Bohm G, Jasarevic Z, Haid A, Gruber C, Postlberger S, Filipits M, Gnant M. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Clin Cancer Res. 2011;17:7828–7834. - PubMed
    1. Bueno-De-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, Van Krimpen C, Meijers C, De Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, De Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, Van De Vijver MJ. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat. 2009;117:483–495. - PubMed
    1. Buyse M, Loi S, Van't Veer L, Viale G, Delorenzi M, Glas AM, D'assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183–1192. - PubMed

Substances